Curaleaf Holdings (CURLF) Non-Current Debt (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Non-Current Debt of $512.9 million for Q4 2025, up 9.86% year-on-year from $466.9 million in Q4 2024, and up 9.86% on a QoQ basis from $466.9 million in Q4 2024.
Curaleaf Holdings (CURLF) Non-Current Debt (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Non-Current Debt for 7 consecutive years, with $512.9 million the latest figure, recorded in Q4 2025.
- Quarterly Non-Current Debt rose 9.86% year-over-year to $512.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $512.9 million (up 9.86% YoY) and the FY2025 annual result came in at $512.9 million, up 9.86% from the prior year.
- Non-Current Debt grew to $512.9 million in Q4 2025 per CURLF's latest filing, from $466.9 million in the prior quarter.
- Over the last five years, Non-Current Debt for CURLF reached as high as $582.0 billion in Q1 2022 and fell as low as $335.3 million in Q1 2021.
- A 5-year average of $39.2 billion and a median of $512.9 million in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt soared 173458.09% — and 2024, when it slipped 14.84%.
- Year by year, Non-Current Debt stood at $457.9 million in 2021, then climbed by 24.65% to $570.8 million in 2022, then retreated by 3.94% to $548.3 million in 2023, then decreased by 14.84% to $466.9 million in 2024, then advanced by 9.86% to $512.9 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $512.9 million, $466.9 million, and $461.5 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 512.92 Mn |
| Dec 31, 2024 | 466.90 Mn |
| Sep 30, 2024 | 461.48 Mn |
| Jun 30, 2024 | 460.32 Mn |
| Dec 31, 2023 | 548.29 Mn |
| Sep 30, 2023 | 522.38 Mn |
| Jun 30, 2023 | 525.60 Mn |
| Dec 31, 2022 | 570.79 Mn |
| Sep 30, 2022 | 597.18 Mn |
| Jun 30, 2022 | 584.95 Mn |
| Mar 31, 2022 | 581.98 Bn |
| Dec 31, 2021 | 457.92 Mn |
| Sep 30, 2021 | 340.25 Mn |
| Jun 30, 2021 | 336.45 Mn |
| Mar 31, 2021 | 335.32 Mn |
| Dec 31, 2020 | 285.00 Mn |
| Sep 30, 2020 | 273.70 Mn |
| Dec 31, 2019 | 87.95 Mn |